Core Insights - GSK has launched an innovative initiative focused on multiple myeloma (MM) patients during the 8th China International Import Expo, aiming to enhance patient support through collaboration with the medical community and NGOs [1] - A strategic cooperation memorandum has been signed between GSK and the Beijing Zhongkanglian Public Welfare Foundation to establish an MM working group, improving management levels and reducing the burden on doctors [1] - The injection of mabeparvovec, an ADC drug, is recognized as a first-line treatment for relapsed/refractory MM according to the CSCO guidelines, highlighting the importance of early intervention during the first relapse phase [1] Group 1 - GSK's ADC therapy, mabeparvovec, has been included in the breakthrough therapy category by the National Medical Products Administration of China, with its application for market approval under priority review [2] - The company plans to accelerate research and development in the specialty drug sector [2]

Group 1: GE Healthcare and Alibaba - GE Healthcare signed a cooperation framework agreement with Alibaba's Damo Academy to integrate the "one scan, multiple checks" AI technology into advanced imaging equipment [1] Group 2: Nissan and Automotive Industry - Nissan established a joint venture, Nissan Import and Export (Guangzhou) Co., marking the first joint venture for foreign car manufacturers in China [2] - The first products to be exported from China include the Dongfeng Nissan N7 and Frontier Pro PHEV [2] Group 3: E-commerce and Retail - Taobao Flash Sale launched a program to provide new uniforms for 1 million active delivery riders, enhancing their equipment experience [3] - Huawei's 3,000 stores across 247 cities joined Taobao Flash Sale, offering rapid delivery services with a week-on-week sales increase of 1910% [5] Group 4: Aviation Industry - China Southern Airlines Group signed 23 import procurement agreements with a total value exceeding $2 billion, setting a new high in six years [7] - Cathay Pacific announced a buyback of shares from Qatar Airways, totaling approximately HKD 6.97 billion for 643,076,181 shares [4] Group 5: Pharmaceuticals and Healthcare - GlaxoSmithKline showcased multiple innovative vaccines and drugs at the China International Import Expo, including the first RSV vaccine approved for market [6] Group 6: Technology and AI - iFlytek launched a new multimodal digital human guide named "Xiao Fei," capable of multi-person dialogue and personalized memory [10] - iFlytek also released the Spark X1.5 deep reasoning model, achieving over 93% efficiency compared to international competitors [10] Group 7: Investment and Financing - Wireless Logic secured €2 billion in private equity funding, with a valuation of approximately £3.5 billion [9] - Ares Management Corp. is seeking to enhance its credit business in the Asia-Pacific region by recruiting a partner-level executive [9]

北京商报讯（记者 王寅浩 宋雨盈）11月6日，第八届中国国际进口博览会（以下简称"进博会"）葛兰素 史克（以下简称"GSK"）展台正式揭幕，今年GSK以"合力超越，创健未来"为主题，展台呈现了其在防 治结合、全生命周期健康管理方面的布局和理念。据悉，这已经是GSK连续八年参展进博会。 本届进博会上，GSK带来了多款创新管线产品。其中包括全球首款获批上市、在中国首个开展三期临床 的呼吸道合胞病毒（RSV）疫苗，全球首个有望实现慢性乙型肝炎"功能性治愈"的反义寡核苷酸 （ASO）类药物，可实现六个月一次长效给药的德莫奇单抗，以及针对多发性骨髓瘤的全球首个抗 BCMA抗体偶联药物注射用玛贝兰妥单抗，覆盖呼吸、免疫与炎症，感染性疾病，肿瘤等多个治疗领 域。 此外，曾在进博会展出过的重组带状疱疹疫苗欣安立适、新可来（美泊利珠单抗）此次也将携新适应症 再度亮相本届进博会。 GSK近年来积极拓展本土合作，与智飞生物推进带状疱疹疫苗可及性，今年，更与恒瑞医药达成合作， 将共同开发至多12款涵盖呼吸、自免和炎症、肿瘤治疗领域的创新药物。 目前，GSK超过80%的中国研发项目已并入全球同步开发，同时，始终聚焦于慢性乙肝等中国高发 ...